To the Editor: In concluding that the current process for making decisions about coverage of high-dose chemotherapy for breast cancer is “arbitrary and capricious,” Drs. Peters and Rogers (Feb. 17 issue)1 assume that … only insurers have a financial interest in making determinations about coverage. At the commonly quoted price of $150,000 per course of treatment, however, treatment of the 533 women in their analysis represents an annual income of $20 million to their institution alone. Institutions, providers, and suppliers all benefit substantially from insurance coverage for this treatment. Though the authors indicate otherwise, publication of their article.
ASJC Scopus subject areas